{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:14:12Z","timestamp":1790892852781,"version":"4.1.0"},"reference-count":115,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Alpha-synuclein (\u03b1-syn) aggregation products may cause neural injury and\nseveral neurodegenerative disorders (NDs) known as \u03b1-synucleinopathies. Alkaloids are secondary\nmetabolites present in a variety of plant species and may positively affect human health, particularly\n\u03b1-synucleinopathy-associated NDs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>To summarize the latest scientific data on the inhibitory properties of alkaloids in \u03b1-\nsynucleinopathies, especially in Parkinson\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Literature search was performed using web-based databases including Web of Science,\nPubMed, and Scopus up to January 2024, in the English language.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Harmala alkaloids, caffein, lycorine, piperin, acetylcorynoline, berberin, papaverine, squalamine,\ntrodusquemine and nicotin have been found to be the most active natural alkaloids against\nsynucleinopathy. The underlying mechanisms that contribute to this effect would be the inhibition\nof \u03b1-syn aggregation; elimination of formed aggregates; improvement in autophagy activation; promotion\nof the activity and expression of antioxidative enzymes; and prevention of oxidative injury\nand apoptosis in dopaminergic neurons.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The findings of the present study highlight the inhibitory activities of alkaloids against\nsynucleinopathy. However, no clinical data supports the reported activities in humans, which calls\nattention to the need for conducting clinical trials to elucidate the efficacy, safety, proper dosage,\nunwanted effects and pharmacokinetics aspects of alkaloids in humans.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113895575306884240604065754","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:00:01Z","timestamp":1718362801000},"page":"112-127","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Review of the Protective Effects of Alkaloids against Alpha-synuclein Toxicity in Parkinson's Disease"],"prefix":"10.2174","volume":"25","author":[{"given":"Mahdi","family":"Khodadadi","sequence":"first","affiliation":[{"name":"Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-3215","authenticated-orcid":true,"given":"Behjat","family":"Javadi","sequence":"additional","affiliation":[{"name":"Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/978-94-007-5416-4_16","volume":"65","author":"Mhyre T.R.","year":"2012","unstructured":"Mhyre T.R.; Boyd J.T.; Hamill R.W.; Zeiss M.K.A.; Parkinson\u2019s disease. Subcell Biochem  2012,65,389-455","journal-title":"Subcell Biochem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"Rizek P.","year":"2016","unstructured":"Rizek P.; Kumar N.; Jog M.S.; An update on the diagnosis and treatment of Parkinson disease. CMAJ  2016,188(16),1157-1165","journal-title":"CMAJ"},{"key":"ref=3","first-page":"3","author":"Kouli A.","year":"2018","unstructured":"Kouli A.; Torsney K.M.; Kuan W-L.;  Parkinson\u2019s disease: Etiology, neuropathology, and pathogenesis  2018,3-26","journal-title":"Parkinson\u2019s disease: Etiology, neuropathology, and pathogenesis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s11033-020-05284-y","volume":"47","author":"Ramazani E.","year":"2020","unstructured":"Ramazani E.; YazdFazeli, M.; Emami, S.A.; Mohtashami, L.; Javadi, B.; Asili, J.; Najaran, T.Z. Protective effects of Cinnamomum verum, Cinnamomum cassia and cinnamaldehyde against 6-OHDA-induced apoptosis in PC12 cells. Mol Biol Rep  2020,47(4),2437-2445","journal-title":"Mol Biol Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neurol.2017.12.003","volume":"174","author":"Alexoudi A.","year":"2018","unstructured":"Alexoudi A.; Alexoudi I.; Gatzonis S.; Parkinson\u2019s disease pathogenesis, evolution and alternative pathways: A review. Rev Neurol  2018,174(10),699-704","journal-title":"Rev Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2174\/1381612824666180820150150","volume":"24","author":"Kabra A.","year":"2018","unstructured":"Kabra A.; Sharma R.; Kabra R.; Baghel U.S.; Emerging and alternative therapies for Parkinson disease: An updated review. Curr Pharm Des  2018,24(22),2573-2582","journal-title":"Curr Pharm Des"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00702-017-1717-8","volume":"124","author":"Heim B.","year":"2017","unstructured":"Heim B.; Krismer F.; De Marzi R.; Seppi K.; Magnetic resonance imaging for the diagnosis of Parkinson\u2019s disease. J Neural Transm  2017,124(8),915-964","journal-title":"J Neural Transm"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.20517\/2347-8659.2020.58","volume":"8","author":"Lee T.K.","year":"2022","unstructured":"Lee T.K.; Yankee E.L.; A review on Parkinson\u2019s disease treatment. Neuroimmunol Neuroinflamm  2022,8,222","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"104782","DOI":"10.1016\/j.nbd.2020.104782","volume":"137","author":"Ciga B.S.","year":"2020","unstructured":"Ciga B.S.; Fairen D.M.; Kim J.J.; Singleton A.B.; Genetics of Parkinson\u2019s disease: An introspection of its journey towards precision medicine. Neurobiol Dis  2020,137,104782","journal-title":"Neurobiol Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphar.2020.00356","volume":"11","author":"Benito G.M.","year":"2020","unstructured":"Benito G.M.; Granado N.; Sanz G.P.; Michel A.; Dumoulin M.; Moratalla R.; Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front Pharmacol  2020,11,356","journal-title":"Front Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2174\/1389557522666220523112027","volume":"23","author":"Ghaderi M.A.","year":"2023","unstructured":"Ghaderi M.A.; Emami S.A.; Olia B.M.D.; Javadi B.; The role of sesamin in targeting neurodegenerative disorders: A systematic review. Mini Rev Med Chem  2023,23(6),756-770","journal-title":"Mini Rev Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","volume":"7","author":"Goedert M.","year":"2017","unstructured":"Goedert M.; Jakes R.; Spillantini M.G.; The synucleinopathies: Twenty years on. J Parkinsons Dis  2017,7(s1),S51-S69","journal-title":"J Parkinsons Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"Wong Y.C.","year":"2017","unstructured":"Wong Y.C.; Krainc D.; &#x3B1;-synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies. Nat Med  2017,23(2),1-13","journal-title":"Nat Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JPD-150642","volume":"5","author":"Burr&#xE9; J.","year":"2015","unstructured":"Burr&#xE9; J.; The synaptic function of &#x3B1;-synuclein. J Parkinsons Dis  2015,5(4),699-713","journal-title":"J Parkinsons Dis"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3390\/cells10092229","volume":"10","author":"Popova B.","year":"2021","unstructured":"Popova B.; Galka D.; H&#xE4;ffner, N.; Wang, D.; Schmitt, K.; Valerius, O. &#x3B1;-Synuclein decreases the abundance of proteasome subunits and alters ubiquitin conjugates in yeast. Cells  2021,10(9),2229","journal-title":"Cells"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.3390\/ijms20215312","volume":"20","author":"Lin K.J.","year":"2019","unstructured":"Lin K.J.; Lin K.L.; Chen S.D.; Liou C.W.; Chuang Y.C.; Lin H.Y.; The overcrowded crossroads: Mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson\u2019s disease. Int. J Mol Sci  2019,20(21),5312","journal-title":"J Mol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"Devi L.","year":"2008","unstructured":"Devi L.; Raghavendran V.; Prabhu B.M.; Avadhani N.G.; Anandatheerthavarada H.K.; Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem  2008,283(14),9089-9100","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/biom11050718","volume":"11","author":"Risiglione P.","year":"2021","unstructured":"Risiglione P.; Zinghirino F.; Di Rosa M.C.; Magr&#xEC; A.; Messina A.; Alpha-synuclein and mitochondrial dysfunction in parkinson\u2019s disease: The emerging role of VDAC. Biomolecules  2021,11(5),718","journal-title":"Biomolecules"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1523\/JNEUROSCI.0954-20.2020","volume":"40","author":"Tsunemi T.","year":"2020","unstructured":"Tsunemi T.; Ishiguro Y.; Yoroisaka A.; Valdez C.; Miyamoto K.; Ishikawa K.; Saiki S.; Akamatsu W.; Hattori N.; Krainc D.; Astrocytes protect human dopaminergic neurons from &#x3B1;-synuclein accumulation and propagation. J Neurosci  2020,40(45),8618-8628","journal-title":"J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"Lashuel H.A.","year":"2013","unstructured":"Lashuel H.A.; Overk C.R.; Oueslati A.; Masliah E.; The many faces of &#x3B1;-synuclein: From structure and toxicity to therapeutic target. Nat Rev Neurosci  2013,14(1),38-48","journal-title":"Nat Rev Neurosci"},{"key":"ref=21","author":"Manske R.H.F.","year":"2014","unstructured":"Manske R.H.F.; Holmes H.L.;  The alkaloids: Chemistry and physiology  2014","journal-title":"The alkaloids: Chemistry and physiology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuint.2015.07.018","volume":"89","author":"Ng Y.P.","year":"2015","unstructured":"Ng Y.P.; Or T.C.T.; Ip N.Y.; Plant alkaloids as drug leads for Alzheimer\u2019s disease. Neurochem Int  2015,89,260-270","journal-title":"Neurochem Int"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.parkreldis.2020.10.024","volume":"80","author":"Chen J.F.","year":"2020","unstructured":"Chen J.F.; Schwarzschild M.A.; Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson\u2019s disease? Parkinson. Relat Disord  2020,80(S1),S45-S53","journal-title":"Relat Disord"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"Stefanis L.","year":"2012","unstructured":"Stefanis L.; &#x3B1;-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med  2012,2(2),a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nbd.2015.12.018","volume":"88","author":"Mor D.E.","year":"2016","unstructured":"Mor D.E.; Ugras S.E.; Daniels M.J.; Ischiropoulos H.; Dynamic structural flexibility of &#x3B1;-synuclein. Neurobiol Dis  2016,88,66-74","journal-title":"Neurobiol Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1110\/ps.052048706","volume":"15","author":"Bisaglia M.","year":"2006","unstructured":"Bisaglia M.; Trolio A.; Bellanda M.; Bergantino E.; Bubacco L.; Mammi S.; Structure and topology of the non\u2010amyloid\u2010&#x3B2; component fragment of human &#x3B1;\u2010synuclein bound to micelles: Implications for the aggregation process. Protein Sci  2006,15(6),1408-1416","journal-title":"Protein Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.procbio.2021.08.008","volume":"110","author":"Singh A.","year":"2021","unstructured":"Singh A.; Maharana S.K.; Shukla R.; Kesharwani P.; Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease. Process Biochem  2021,110,181-194","journal-title":"Process Biochem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/1735-1995.181989","volume":"21","author":"Emamzadeh F.","year":"2016","unstructured":"Emamzadeh F.; Alpha-synuclein structure, functions, and interactions. J Res Med Sci  2016,21(1),29","journal-title":"J Res Med Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"736978","DOI":"10.3389\/fmed.2021.736978","volume":"8","author":"Srinivasan E.","year":"2021","unstructured":"Srinivasan E.; Chandrasekhar G.; Chandrasekar P.; Anbarasu K.; Vickram A.S.; Karunakaran R.; Rajasekaran R.; Srikumar P.S.; Alpha-synuclein aggregation in Parkinson\u2019s disease. Front Med  2021,8,736978","journal-title":"Front Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1074\/jbc.M411805200","volume":"280","author":"Ulmer T.S.","year":"2005","unstructured":"Ulmer T.S.; Bax A.; Cole N.B.; Nussbaum R.L.; Structure and dynamics of micelle-bound human &#x3B1;-synuclein. J Biol Chem  2005,280(10),9595-9603","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","volume":"1822","author":"Breydo L.","year":"2012","unstructured":"Breydo L.; Wu J.W.; Uversky V.N.; &#x3B1;-Synuclein misfolding and Parkinson\u2019s disease. Biochim Biophys Acta Mol Basis Dis  2012,1822(2),261-285","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2018.09.014","volume":"100","author":"Nuber S.","year":"2018","unstructured":"Nuber S.; Rajsombath M.; Minakaki G.; Winkler J.; M&#xFC;ller C.P.; Ericsson M.; Abrogating native &#x3B1;-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson\u2019s disease. Neuron  e52018,100(1),75-90","journal-title":"Neuron"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.cub.2014.08.027","volume":"24","author":"Wang L.","year":"2014","unstructured":"Wang L.; Das U.; Scott D.A.; Tang Y.; McLean P.J.; Roy S.; &#x3B1;-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol  2014,24(19),2319-2326","journal-title":"Curr Biol"},{"key":"ref=34","first-page":"879","volume":"152","author":"Baba M.","year":"1998","unstructured":"Baba M.; Nakajo S.; Tu P.H.; Tomita T.; Nakaya K.; Lee V.M.; Trojanowski J.Q.; Iwatsubo T.; Aggregation of alpha-synuclein in lewy bodies of sporadic Parkinson\u2019s disease and dementia with lewy bodies. Am J Pathol  1998,152(4),879-884","journal-title":"Am J Pathol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"Alam P.","year":"2019","unstructured":"Alam P.; Bousset L.; Melki R.; Otzen D.E.; &#x3B1;\u2010synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities. J Neurochem  2019,150(5),522-534","journal-title":"J Neurochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"100334","DOI":"10.1016\/j.phanu.2023.100334","volume":"24","author":"Harati M.","year":"2023","unstructured":"Harati M.; Najaran T.Z.; Javadi B.; Dietary flavonoids: Promising compounds for targeting &#x3B1;-synucleinopathy in Parkinson\u2019s disease. PharmaNutrition  2023,24,100334","journal-title":"PharmaNutrition"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fnins.2019.01399","volume":"13","author":"Conde B.L.D.","year":"2020","unstructured":"Conde B.L.D.; Acevedo R.R.; Hern&#xE1;ndez, R.M.A.; Olvera, B.A.J.; Moreno, M.I.D.; S&#xE1;nchez, A.R.; Sch&#xFC;le, B.; Crespo, G.M. Alpha-synuclein physiology and pathology: A perspective on cellular structures and organelles. Front Neurosci  2020,13,1399","journal-title":"Front Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1126\/science.1063522","volume":"294","author":"Conway K.A.","year":"2001","unstructured":"Conway K.A.; Rochet J.C.; Bieganski R.M.; Lansbury P.T.; Kinetic stabilization of the &#x3B1;-synuclein protofibril by a dopamine-&#x3B1;-synuclein adduct. Science  2001,294(5545),1346-1349","journal-title":"Science"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"Schulz-Schaeffer W.J.","year":"2010","unstructured":"Schulz-Schaeffer W.J.; The synaptic pathology of &#x3B1;-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol  2010,120(2),131-143","journal-title":"Acta Neuropathol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"Jankovic J.","year":"2020","unstructured":"Jankovic J.; Tan E.K.; Parkinson\u2019s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry  2020,91(8),795-808","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mds.26479","volume":"31","author":"Calo L.","year":"2016","unstructured":"Calo L.; Wegrzynowicz M.; Perez S.J.; Spillantini G.M.; Synaptic failure and &#x3B1;\u2010synuclein. Mov Disord  2016,31(2),169-177","journal-title":"Mov Disord"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/ptr.7425","volume":"36","author":"Iranshahy M.","year":"2022","unstructured":"Iranshahy M.; Javadi B.; Sahebkar A.; Protective effects of functional foods against Parkinson\u2019s disease: A narrative review on pharmacology, phytochemistry, and molecular mechanisms. Phytother Res  2022,36(5),1952-1989","journal-title":"Phytother Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fnins.2019.00328","volume":"13","author":"Alecu I.","year":"2019","unstructured":"Alecu I.; Bennett S.A.L.; Dysregulated lipid metabolism and its role in &#x3B1;-synucleinopathy in Parkinson\u2019s disease. Front Neurosci  2019,13,328","journal-title":"Front Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fnagi.2018.00370","volume":"10","author":"Zhang G.","year":"2018","unstructured":"Zhang G.; Xia Y.; Wan F.; Ma K.; Guo X.; Kou L.; Yin S.; Han C.; Liu L.; Huang J.; Xiong N.; Wang T.; New perspectives on roles of alpha-synuclein in Parkinson\u2019s disease. Front Aging Neurosci  2018,10,370","journal-title":"Front Aging Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/jnc.15181","volume":"157","author":"Melland H.","year":"2021","unstructured":"Melland H.; Arvell E.H.; Gordon S.L.; Disorders of synaptic vesicle fusion machinery. J Neurochem  2021,157(2),130-164","journal-title":"J Neurochem"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-00139-6","volume":"6","author":"De Miranda B.R.","year":"2020","unstructured":"De Miranda B.R.; Rocha E.M.; Castro S.L.; Greenamyre J.T.; Protection from &#x3B1;-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20. NPJ Parkinsons Dis  2020,6(1),1-10","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=47","first-page":"342ra78","volume":"8","author":"Di Maio R.","year":"2016","unstructured":"Di Maio R.; Barrett P.J.; Hoffman E.K.; Barrett C.W.; Zharikov A.; Borah A.; &#x3B1;-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease. Sci Translat Med  2016,8(342),342ra78-342ra78","journal-title":"Sci Translat Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"Fields C.R.","year":"2019","unstructured":"Fields C.R.; Bengoa-Vergniory N.; Wade-Martins R.; Targeting alpha-synuclein as a therapy for Parkinson\u2019s disease. Front Mol Neurosci  2019,12,299","journal-title":"Front Mol Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/mds.26370","volume":"31","author":"Dehay B.","year":"2016","unstructured":"Dehay B.; Vila M.; Bezard E.; Brundin P.; Kordower J.H.; Alpha\u2010synuclein propagation: New insights from animal models. Mov Disord  2016,31(2),161-168","journal-title":"Mov Disord"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neulet.2019.04.047","volume":"705","author":"Fatima A.","year":"2019","unstructured":"Fatima A.; Rahul; Siddique, Y.H. Role of tangeritin against cognitive impairments in transgenic Drosophila model of Parkinson\u2019s disease. Neurosci Lett  2019,705,112-117","journal-title":"Neurosci Lett"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-00149-4","volume":"7","author":"Cuadrado F.A.","year":"2021","unstructured":"Cuadrado F.A.; Sanchez S.D.; Moriano M.A.; Cenjor L.E.; Olmo L.V.; Marcos M.A.; Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson\u2019s disease. NPJ Parkinsons Dis  2021,7(1),1-13","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.3390\/ijms20215312","volume":"20","author":"Lin K.J.","year":"2019","unstructured":"Lin K.J.; Lin K.L.; Chen S.D.; Liou C.W.; Chuang Y.C.; Lin H.Y.; Lin T.K.; The overcrowded crossroads: Mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson\u2019s disease. Int J Mol Sci  2019,20(21),5312","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"Dzamko N.","year":"2017","unstructured":"Dzamko N.; Gysbers A.; Perera G.; Bahar A.; Shankar A.; Gao J.; Fu Y.; Halliday G.M.; Toll-like receptor 2 is increased in neurons in Parkinson\u2019s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol  2017,133(2),303-319","journal-title":"Acta Neuropathol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neulet.2009.11.034","volume":"469","author":"Koob A.O.","year":"2010","unstructured":"Koob A.O.; Paulino A.D.; Masliah E.; GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with &#x3B1;-synuclein. Neurosci Lett  2010,469(1),11-14","journal-title":"Neurosci Lett"},{"key":"ref=55","year":"2019","unstructured":"Alkaloids - Their importance in nature and for human life. Joanna, K, Ed; Alkaloids  2019","journal-title":"Joanna, K, Ed; Alkaloids"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/molecules26071836","volume":"26","author":"Heinrich M.","year":"2021","unstructured":"Heinrich M.; Mah J.; Amirkia V.; Alkaloids used as medicines: Structural phytochemistry meets biodiversity-An update and forward look. Molecules  2021,26(7),1836","journal-title":"Molecules"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/molecules24040796","volume":"24","author":"Johannsen K.K.L.","year":"2019","unstructured":"Johannsen K.K.L.; Kayser O.; Tropane alkaloids: Chemistry, pharmacology, biosynthesis and production. Molecules  2019,24(4),796","journal-title":"Molecules"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8749083","volume":"2020","author":"Uzor P.F.","year":"2020","unstructured":"Uzor P.F.; Alkaloids from plants with antimalarial activity: A review of recent studies. Evid Based Complement Alternat Med  2020,2020,1-17","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.phrs.2019.04.028","volume":"144","author":"Vitali Serdoz L.","year":"2019","unstructured":"Vitali Serdoz L.; Rittger H.; Furlanello F.; Bastian D.; Quinidine\u2014A legacy within the modern era of antiarrhythmic therapy. Pharmacol Res  2019,144,257-263","journal-title":"Pharmacol Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.bmcl.2018.06.044","volume":"28","author":"Martino E.","year":"2018","unstructured":"Martino E.; Casamassima G.; Castiglione S.; Cellupica E.; Pantalone S.; Papagni F.; Rui M.; Siciliano A.M.; Collina S.; Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead. Bioorg Med Chem Lett  2018,28(17),2816-2826","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/toxins11110656","volume":"11","author":"Thawabteh A.","year":"2019","unstructured":"Thawabteh A.; Juma S.; Bader M.; Karaman D.; Scrano L.; Bufo S.A.; The biological activity of natural alkaloids against herbivores, cancerous cells and pathogens. Toxins  2019,11(11),656","journal-title":"Toxins"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"850949","DOI":"10.3389\/fpls.2022.850949","volume":"13","author":"Song C.","year":"2022","unstructured":"Song C.; Ma J.; Li G.; Pan H.; Zhu Y.; Jin Q.; Cai Y.; Han B.; Natural composition and biosynthetic pathways of alkaloids in medicinal Dendrobium species. Front Plant Sci  2022,13,850949","journal-title":"Front Plant Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e0132","DOI":"10.1199\/tab.0132","volume":"8","author":"Tzin V.","year":"2010","unstructured":"Tzin V.; Galili G.; The biosynthetic pathways for shikimate and aromatic amino acids in Arabidopsis thaliana. Arabidopsis Book  2010,8,e0132","journal-title":"Arabidopsis Book"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1104\/pp.19.00683","volume":"182","author":"Perez de Souza L.","year":"2020","unstructured":"Perez de Souza L.; Garbowicz K.; Brotman Y.; Tohge T.; Fernie A.R.; The acetate pathway supports flavonoid and lipid biosynthesis in arabidopsis. Plant Physiol  2020,182(2),857-869","journal-title":"Plant Physiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/auto.8.1.18313","volume":"8","author":"Lu J.H.","year":"2012","unstructured":"Lu J.H.; Tan J.Q.; Durairajan S.S.K.; Liu L.F.; Zhang Z.H.; Ma L.; Shen H.M.; Chan H.Y.E.; Li M.; Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy  2012,8(1),98-108","journal-title":"Autophagy"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.3390\/molecules26123736","volume":"26","author":"Ghanem S.S.","year":"2021","unstructured":"Ghanem S.S.; Fayed H.S.; Zhu Q.; Lu J.H.; Vaikath N.N.; Ponraj J.; Natural alkaloid compounds as inhibitors for alpha-synuclein seeded fibril formation and toxicity. Molecules  2021,26(12),3736","journal-title":"Molecules"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biomedicines9020099","volume":"9","author":"Devi S.","year":"2021","unstructured":"Devi S.; Kumar V.; Singh S.K.; Dubey A.K.; Kim J.J.; Flavonoids: Potential candidates for the treatment of neurodegenerative disorders. Biomedicines  2021,9(2),99","journal-title":"Biomedicines"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"680026","DOI":"10.3389\/fnins.2021.680026","volume":"15","author":"Limbocker R.","year":"2021","unstructured":"Limbocker R.; Staats R.; Chia S.; Ruggeri F.S.; Mannini B.; Xu C.K.; Perni M.; Cascella R.; Bigi A.; Sasser L.R.; Block N.R.; Wright A.K.; Kreiser R.P.; Custy E.T.; Meisl G.; Errico S.; Habchi J.; Flagmeier P.; Kartanas T.; Hollows J.E.; Nguyen L.T.; LeForte K.; Barbut D.; Kumita J.R.; Cecchi C.; Zasloff M.; Knowles T.P.J.; Dobson C.M.; Chiti F.; Vendruscolo M.; Squalamine and its derivatives modulate the aggregation of amyloid-&#x3B2; and &#x3B1;-synuclein and suppress the toxicity of their oligomers. Front Neurosci  2021,15,680026","journal-title":"Front Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","volume":"114","author":"Perni M.","year":"2017","unstructured":"Perni M.; Galvagnion C.; Maltsev A.; Meisl G.; M&#xFC;ller M.B.D.; Challa P.K.; Kirkegaard J.B.; Flagmeier P.; Cohen S.I.A.; Cascella R.; Chen S.W.; Limbocker R.; Sormanni P.; Heller G.T.; Aprile F.A.; Cremades N.; Cecchi C.; Chiti F.; Nollen E.A.A.; Knowles T.P.J.; Vendruscolo M.; Bax A.; Zasloff M.; Dobson C.M.; A natural product inhibits the initiation of &#x3B1;-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci  2017,114(6),E1009-E1017","journal-title":"Proc Natl Acad Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","volume":"13","author":"Perni M.","year":"2018","unstructured":"Perni M.; Flagmeier P.; Limbocker R.; Cascella R.; Aprile F.A.; Galvagnion C.; Heller G.T.; Meisl G.; Chen S.W.; Kumita J.R.; Challa P.K.; Kirkegaard J.B.; Cohen S.I.A.; Mannini B.; Barbut D.; Nollen E.A.A.; Cecchi C.; Cremades N.; Knowles T.P.J.; Chiti F.; Zasloff M.; Vendruscolo M.; Dobson C.M.; Multistep inhibition of &#x3B1;-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem Biol  2018,13(8),2308-2319","journal-title":"ACS Chem Biol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/mds.10281","volume":"17","author":"Manson A.J.","year":"2002","unstructured":"Manson A.J.; Turner K.; Lees A.J.; Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson\u2019s disease: Long\u2010term follow\u2010up study of 64 patients. Mov Disord  2002,17(6),1235-1241","journal-title":"Mov Disord"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s10571-021-01131-1","volume":"42","author":"Heurtaux T.","year":"2022","unstructured":"Heurtaux T.; Kirchmeyer M.; Koncina E.; Felten P.; Richart L.; Huarte U.O.; Schohn H.; Mittelbronn M.; Apomorphine reduces A53T &#x3B1;-synuclein-induced microglial reactivity through activation of NRF2 signalling pathway. Cell Mol Neurobiol  2022,42(8),2673-2695","journal-title":"Cell Mol Neurobiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fnagi.2017.00176","volume":"9","author":"Subramaniam S.R.","year":"2017","unstructured":"Subramaniam S.R.; Federoff H.J.; Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s disease. Front Aging Neurosci  2017,9,176","journal-title":"Front Aging Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"826289","DOI":"10.3389\/fnins.2022.826289","volume":"16","author":"Kirchweger B.","year":"2022","unstructured":"Kirchweger B.; Klein-Junior L.C.; Pretsch D.; Chen Y.; Cretton S.; Gasper A.L.; Heyden Y.V.; Christen P.; Kirchmair J.; Henriques A.T.; Rollinger J.M.; Azepine-indole alkaloids from Psychotria nemorosa Modulate 5-HT2A receptors and prevent in vivo protein toxicity in transgenic Caenorhabditis elegans. Front Neurosci  2022,16,826289","journal-title":"Front Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.neuropharm.2013.08.007","volume":"82","author":"Fu R.H.","year":"2014","unstructured":"Fu R.H.; Wang Y.C.; Chen C.S.; Tsai R.T.; Liu S.P.; Chang W.L.; Lin H.L.; Lu C.H.; Wei J.R.; Wang Z.W.; Shyu W.C.; Lin S.Z.; Acetylcorynoline attenuates dopaminergic neuron degeneration and &#x3B1;-synuclein aggregation in animal models of Parkinson\u2019s disease. Neuropharmacology  2014,82,108-120","journal-title":"Neuropharmacology"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"110576","DOI":"10.1016\/j.biopha.2020.110576","volume":"130","author":"Leem Y.H.","year":"2020","unstructured":"Leem Y.H.; Park J.S.; Park J.E.; Kim D.Y.; Kang J.L.; Kim H.S.; Papaverine inhibits &#x3B1;-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP\/P mouse model of Parkinson\u2019s disease. Biomed Pharmacother  2020,130,110576","journal-title":"Biomed Pharmacother"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4062\/biomolther.2021.039","volume":"29","author":"Leem Y.H.","year":"2021","unstructured":"Leem Y.H.; Park J.S.; Park J.E.; Kim D.Y.; Kim H.S.; Papaverine exerts neuroprotective effect by inhibiting NLRP3 inflammasome activation in an MPTP-induced microglial priming mouse model challenged with LPS. Biomol Ther  2021,29(3),295-302","journal-title":"Biomol Ther"},{"key":"ref=78","first-page":"2250","volume":"35","author":"Ding K.","year":"2010","unstructured":"Ding K.; Liu L.; Cheng X.; Wang C.; Wang Z.; Investigation on representation methods of dissolubility property of total alkaloid extract from Peganum harmala. Zhongguo Zhongyao Zazhi  2010,35(17),2250-2253","journal-title":"Zhongguo Zhongyao Zazhi"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s12272-020-01283-6","volume":"43","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Li D.; Yu S.; Pharmacological effects of harmine and its derivatives: A review. Arch Pharm Res  2020,43(12),1259-1275","journal-title":"Arch Pharm Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mdc3.12242","volume":"3","author":"Djamshidian A.","year":"2016","unstructured":"Djamshidian A.; Reif B.S.; Poewe W.; Lees A.J.; Banisteriopsis caapi, a forgotten potential therapy for Parkinson\u2019s disease? Mov Disord Clin Pract  2016,3(1),19-26","journal-title":"Mov Disord Clin Pract"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"152842","DOI":"10.1016\/j.phymed.2019.152842","volume":"61","author":"Cai C.Z.","year":"2019","unstructured":"Cai C.Z.; Zhou H.F.; Yuan N.N.; Wu M.Y.; Lee S.M.Y.; Ren J.Y.; Su H.X.; Lu J.J.; Chen X.P.; Li M.; Tan J.Q.; Lu J.H.; Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine  2019,61,152842","journal-title":"Phytomedicine"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"153578","DOI":"10.1016\/j.phymed.2021.153578","volume":"87","author":"Zhu Q.","year":"2021","unstructured":"Zhu Q.; Zhuang X.; Chen J.; Yuan N.; Chen Y.; Cai C.; Tan J.; Su H.; Lu J.; Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson\u2019s disease models. Phytomedicine  2021,87,153578","journal-title":"Phytomedicine"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41531-022-00361-4","volume":"8","author":"Xu J.","year":"2022","unstructured":"Xu J.; Ao Y.L.; Huang C.; Song X.; Zhang G.; Cui W.; Wang Y.; Zhang X-Q.; Zhang Z.; Harmol promotes &#x3B1;-synuclein degradation and improves motor impairment in Parkinson\u2019s models via regulating autophagy-lysosome pathway. NPJ Parkinsons Dis  2022,8(1),100","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1002\/fsn3.3031","volume":"10","author":"Abulimiti G.","year":"2022","unstructured":"Abulimiti G.; Zeng J.; Aimaiti M.; Lei X.; Mi N.; Harmol hydrochloride dihydrate induces autophagy in neuro cells and promotes the degradation of &#x3B1;\u2010Syn by Atg5\/Atg12\u2010dependent pathway. Food Sci Nutr  2022,10(12),4371-4379","journal-title":"Food Sci Nutr"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"8366","DOI":"10.1039\/D1FO01360B","volume":"12","author":"Deng H.","year":"2021","unstructured":"Deng H.; Ma Z.; Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice. Food Funct  2021,12(18),8366-8375","journal-title":"Food Funct"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"117628","DOI":"10.1016\/j.jep.2023.117628","volume":"322","author":"Yu L.","year":"2024","unstructured":"Yu L.; Hu X.; Xu R.; Zhao Y.; Xiong L.; Ai J.; Wang X.; Chen X.; Ba Y.; Xing Z.; Guo C.; Mi S.; Wu X.; Piperine promotes PI3K\/AKT\/mTOR-mediated gut-brain autophagy to degrade &#x3B1;-Synuclein in Parkinson\u2019s disease rats. J Ethnopharmacol  2024,322,117628","journal-title":"J Ethnopharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13765-022-00710-0","volume":"65","author":"Huang L.","year":"2022","unstructured":"Huang L.; Zhong X.; Zhou Z.; Cai Y.; Deng M.; Piperine increases striatal levels of DA and TH and decreases &#x3B1;-syn and A&#x3B2;42 deposition in PDD mice by regulting autophagy: Downexpression Beclin-1 and LC3B and upexpression p62. Appl Biol Chem  2022,65(1),42","journal-title":"Appl Biol Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/15548627.2021.1937897","volume":"18","author":"Li R.","year":"2022","unstructured":"Li R.; Lu Y.; Zhang Q.; Liu W.; Yang R.; Jiao J.; Liu J.; Gao G.; Yang H.; Piperine promotes autophagy flux by P2RX4 activation in SNCA\/&#x3B1;-synuclein-induced Parkinson disease model. Autophagy  2022,18(3),559-575","journal-title":"Autophagy"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1021\/acschemneuro.5b00158","volume":"6","author":"Kardani J.","year":"2015","unstructured":"Kardani J.; Roy I.; Understanding caffeine\u2019s role in attenuating the toxicity of &#x3B1;-synuclein aggregates: Implications for risk of Parkinson\u2019s disease. ACS Chem Neurosci  2015,6(9),1613-1625","journal-title":"ACS Chem Neurosci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fnins.2018.00301","volume":"12","author":"Luan Y.","year":"2018","unstructured":"Luan Y.; Ren X.; Zheng W.; Zeng Z.; Guo Y.; Hou Z.; Guo W.; Chen X.; Li F.; Chen J.F.; Chronic caffeine treatment protects against &#x3B1;-synucleinopathy by reestablishing autophagy activity in the mouse striatum. Front Neurosci  2018,12,301","journal-title":"Front Neurosci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"104538","DOI":"10.1016\/j.phrs.2019.104538","volume":"150","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Wu Q.; Zhang L.; Wang Q.; Yang Z.; Liu J.; Feng L.; Caffeic acid reduces A53T &#x3B1;-synuclein by activating JNK\/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease. Pharmacol Res  2019,150,104538","journal-title":"Pharmacol Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"E12053","DOI":"10.1073\/pnas.1813365115","volume":"115","author":"Yan R.","year":"2018","unstructured":"Yan R.; Zhang J.; Park H.J.; Park E.S.; Oh S.; Zheng H.; Junn E.; Voronkov M.; Stock J.B.; Mouradian M.M.; Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson\u2019s disease and DLB. Proc Natl Acad Sci  2018,115(51),E12053-E12062","journal-title":"Proc Natl Acad Sci"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","volume":"2009","author":"Benowitz N.L.","year":"2009","unstructured":"Benowitz N.L.; Hukkanen J.; Jacob P.; III Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol  2009,2009(192),29-60","journal-title":"Handb Exp Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/mds.29283","volume":"38","author":"Olsen A.L.","year":"2023","unstructured":"Olsen A.L.; Clemens S.G.; Feany M.B.; Nicotine\u2010mediated rescue of &#x3B1;\u2010synuclein toxicity requires synaptic vesicle glycoprotein 2 in Drosophila. Mov Disord  2023,38(2),244-255","journal-title":"Mov Disord"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2019.04.017","volume":"129","author":"Bono F.","year":"2019","unstructured":"Bono F.; Mutti V.; Savoia P.; Barbon A.; Bellucci A.; Missale C.; Fiorentini C.; Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer. Neurobiol Dis  2019,129,1-12","journal-title":"Neurobiol Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nbd.2018.05.018","volume":"117","author":"Subramaniam S.R.","year":"2018","unstructured":"Subramaniam S.R.; Magen I.; Bove N.; Zhu C.; Lemesre V.; Dutta G.; Elias C.J.; Lester H.A.; Chesselet M.F.; Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type &#x3B1;-synuclein. Neurobiol Dis  2018,117,170-180","journal-title":"Neurobiol Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.02.002","volume":"1863","author":"Kardani J.","year":"2017","unstructured":"Kardani J.; Sethi R.; Roy I.; Nicotine slows down oligomerisation of &#x3B1;-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson\u2019s disease. Biochim Biophys Acta Mol Basis Dis  2017,1863(6),1454-1463","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.3390\/ijms24044204","volume":"24","author":"Lai J.I.C.","year":"2023","unstructured":"Lai J.I.C.; Porcu A.; Romoli B.; Keisler M.; Manfredsson F.P.; Powell S.B.; Dulcis D.; Nicotine-mediated recruitment of GABAergic neurons to a dopaminergic phenotype attenuates motor deficits in an alpha-synuclein Parkinson\u2019s model. Int J Mol Sci  2023,24(4),4204","journal-title":"Int J Mol Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3390\/nu12061707","volume":"12","author":"Huang C.Y.","year":"2020","unstructured":"Huang C.Y.; Sivalingam K.; Shibu M.A.; Liao P.H.; Ho T.J.; Kuo W.W.; Chen R.J.; Day C.H.; Viswanadha V.P.; Ju D.T.; Induction of autophagy by vasicinone protects neural cells from mitochondrial dysfunction and attenuates paraquat-mediated Parkinson\u2019s disease associated &#x3B1;-synuclein levels. Nutrients  2020,12(6),1707","journal-title":"Nutrients"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1166\/jbt.2020.2367","volume":"10","author":"Jing H.","year":"2020","unstructured":"Jing H.; Maodong W.; Zhenjie S.; Aimin L.; Protective effect of aloperine on dopamine neurons of Parkinson\u2019s disease by activating autophagy. J Biomater Tissue Eng  2020,10(5),602-608","journal-title":"J Biomater Tissue Eng"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"Outeiro T.F.","year":"2019","unstructured":"Outeiro T.F.; Koss D.J.; Erskine D.; Walker L.; Akanbi K.M.; Burn D.; Donaghy P.; Morris C.; Taylor J.P.; Thomas A.; Attems J.; McKeith I.; Dementia with Lewy bodies: An update and outlook. Mol Neurodegener  2019,14(1),5","journal-title":"Mol Neurodegener"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"671498","DOI":"10.3389\/fphar.2021.671498","volume":"12","author":"Alam S.","year":"2021","unstructured":"Alam S.; Sarker M.M.R.; Afrin S.; Richi F.T.; Zhao C.; Zhou J.R.; Mohamed I.N.; Traditional herbal medicines, bioactive metabolites, and plant products against COVID-19: Update on clinical trials and mechanism of actions. Front Pharmacol  2021,12,671498","journal-title":"Front Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/ijbs.23247","volume":"14","author":"Hussain G.","year":"2018","unstructured":"Hussain G.; Rasul A.; Anwar H.; Aziz N.; Razzaq A.; Wei W.; Ali M.; Li J.; Li X.; Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. Int J Biol Sci  2018,14(3),341-357","journal-title":"Int J Biol Sci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3390\/pharmaceutics14102067","volume":"14","author":"Bali Z.K.","year":"2022","unstructured":"Bali Z.K.; Bruszt N.; K\u0151szegi Z.; Nagy L.V.; Atlasz T.; Kov&#xE1;cs P.; Aconitum alkaloid songorine exerts potent gamma-aminobutyric acid-A receptor agonist action in vivo and effectively decreases anxiety without adverse sedative or psychomotor effects in the rat. Pharmaceutics  2022,14(10),2067","journal-title":"Pharmaceutics"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7299778","volume":"2022","author":"Aryal B.","year":"2022","unstructured":"Aryal B.; Raut B.K.; Bhattarai S.; Bhandari S.; Tandan P.; Gyawali K.; Sharma K.; Ranabhat D.; Thapa R.; Aryal D.; Ojha A.; Devkota H.P.; Parajuli N.; Potential therapeutic applications of plant-derived alkaloids against inflammatory and neurodegenerative diseases. Evid Based Complement Alternat Med  2022,2022,1-18","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/1389557523666230725113446","volume":"24","author":"Khaafi M.","year":"2024","unstructured":"Khaafi M.; Najaran T.Z.; Javadi B.; Cinnamaldehyde as a promising dietary phytochemical against metabolic syndrome: A systematic review. Mini Rev Med Chem  2024,24(3),355-369","journal-title":"Mini Rev Med Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jep.2017.03.049","volume":"203","author":"Li S.","year":"2017","unstructured":"Li S.; Cheng X.; Wang C.; A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus Peganum. J Ethnopharmacol  2017,203,127-162","journal-title":"J Ethnopharmacol"},{"key":"ref=108","first-page":"1","volume":"1","author":"Mahmoudian M.","year":"2002","unstructured":"Mahmoudian M.; Salehian P.; Jalilpour H.; Toxicity of peganum harmala: Review and a case report. Iran J. Pharmacol Therap  2002,1,1-4","journal-title":"Pharmacol Therap"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3390\/foods10092121","volume":"10","author":"Ziegenhagen R.","year":"2021","unstructured":"Ziegenhagen R.; Heimberg K.; Lampen A.; Ernst H.K.I.; Safety aspects of the use of isolated piperine ingested as a bolus. Foods  2021,10(9),2121","journal-title":"Foods"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.3390\/molecules28073149","volume":"28","author":"Ashrafi S.","year":"2023","unstructured":"Ashrafi S.; Alam S.; Sultana A.; Raj A.; Emon N.U.; Richi F.T.; Sharmin T.; Moon M.; Park M.N.; Kim B.; Papaverine: A miraculous alkaloid from opium and its multimedicinal application. Molecules  2023,28(7),3149","journal-title":"Molecules"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2221-1691(13)60060-X","volume":"3","author":"Kesarwani K.","year":"2013","unstructured":"Kesarwani K.; Gupta R.; Mukerjee A.; Bioavailability enhancers of herbal origin: An overview. Asian Pac J Trop Biomed  2013,3(4),253-266","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2174\/1389557523666230330113611","volume":"23","author":"Khaafi F.","year":"2023","unstructured":"Khaafi F.; Javadi B.; Molecular targets underlying the neuroprotective effects of boswellic acid: A systematic review. Mini Rev Med Chem  2023,23(19),1912-1925","journal-title":"Mini Rev Med Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1016\/j.bmcl.2012.02.090","volume":"22","author":"Mu L.H.","year":"2012","unstructured":"Mu L.H.; Wang B.; Ren H.Y.; Liu P.; Guo D.H.; Wang F.M.; Bai L.; Guo Y.S.; Synthesis and inhibitory effect of piperine derivates on monoamine oxidase. Bioorg Med Chem Lett  2012,22(9),3343-3348","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jep.2004.01.013","volume":"91","author":"Kong L.D.","year":"2004","unstructured":"Kong L.D.; Cheng C.H.K.; Tan R.X.; Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J Ethnopharmacol  2004,91(2-3),351-355","journal-title":"J Ethnopharmacol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3390\/nu12061707","volume":"12","author":"Huang C.Y.","year":"2020","unstructured":"Huang C.Y.; Sivalingam K.; Shibu M.A.; Liao P.H.; Ho T.J.; Kuo W.W.; Induction of autophagy by vasicinone protects neural cells from mitochondrial dysfunction and attenuates paraquat-mediated parkinson\u2019s disease associated &#x3B1;-synuclein levels. Nutrients  2020,12(6),1707","journal-title":"Nutrients"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575306884240604065754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231021\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575306884240604065754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T13:38:50Z","timestamp":1735479530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231021\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575306884240604065754","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}